Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 18/9/2020
SIETES contiene 93096 citas

 
 
 1 a 20 de 62 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Wang Y-H, Wintzell V, Ludvigsson JF, Svanström H, Pasterenak B. Association between proton pump inhibitor use and risk of fracture in children. JAMA Pediatrics 2020:1. [Ref.ID 103566]
2. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
3. Cita con resumen
Torvinen-Kiskinen S, Tolppanen A-M, Koponen M, Tanskanen A, Tihonen J, Hartikainen S, Taipale H. Proton pump inhibitor use and risk of hip fractures among community-dwelling persons with Alzheimer's disease—a nested case-control study. Aliment Pharmacol Ther 2018;47:1135-42. [Ref.ID 102491]
4. Cita con resumen
Anónimo. Comparative effectiveness of proton pump inhibitors. Therapeutics Initiative Evidence Based Drug Therapy 2016;99:1-2. [Ref.ID 100573]
5.Tiene citas relacionadas Cita con resumen
Kuller LH. Do proton pump inhibitors increase the risk of dementia?. JAMA Neurology 2016;73:379-81. [Ref.ID 100322]
6.Tiene citas relacionadas Cita con resumen
Gomm W, von Holt K, Thomé F, Broich K, Maier W, Fink A, Doblhammer G, Haenisch B. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. JAMA Neurology 2016;73:410-6. [Ref.ID 100299]
7.Enlace a cita original Cita con resumen
Begley J, Smith T, Burnett K, Strike P, Azim A, Spake C, Richardson T. Proton pump inhibitor hypomagnasemia - a cause for concern?. Br J Clin Pharmacol 2016;81:753-8. [Ref.ID 100179]
8. Cita con resumen
Xie Y, Bowe B, Li T, Xian H, Balasubramanian S, Al-Aly Z. Proton pump inhibitors and risk of incident CKD and progression to ESRD. J Am Soc Nephrol 2016:14 de abril. [Ref.ID 100161]
9. Cita con resumen
Hesdorffer CS, Longo DL. Drug-induced megaloblastic anemia. N Engl J Med 2015;373:1649-58. [Ref.ID 99629]
10. Cita con resumen
Anónimo. Consolidations de fracture retardées par des médicaments. Prescrire 2015;35:507-12. [Ref.ID 99440]
11. Cita con resumen
Anónimo. Which PPI?. Med Lett Drugs Ther 2015;57:8-9. [Ref.ID 99216]
12. Cita con resumen
Shah NH, LePendu P, Bauer-Mehren A, Ghebremariam YT, Iyer SV, Marcus J, Nead KT, Cooke JP, Leeper NJ. Proton pump inhibitor usage and the risk of myocardial infarction in the general population. PLoS One 2015:10 de junio. [Ref.ID 99197]
13.Tiene citas relacionadas Cita con resumen
Maggio M, Corsonello A, Ceda GP, Cattabiani C, Lauretani F, Buttò V, Ferrucci L, Bandinelli S, Abbatecola AM, Spazzafumo L, Lattanzio F. Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. JAMA Intern Med 2013;173:518-23. [Ref.ID 95257]
14. Cita con resumen
Uotani T, Sugimoto M, Nishino M, Kodaira C, Yamade M, Sahara S, Yamada T, Osawa S, Sugimoto K, Tanaka T, Umemura K, Watanabe H, Miyajima H, Furuta T. Ability of rabeprazole to prevent gastric mucosal damage from clopidogrel and low doses of aspirin depends on CYP2C19 genotype. Clin Gastroenterol Hepatol 2012;10:879-85. [Ref.ID 92939]
15.Enlace a cita original Cita con resumen
Anónimo. Riesgo de hipomagnesemia asociado a los medicamentos inhibidores de la bomba de protones (IBP). Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2011:1-3. [Ref.ID 91777]
16.
Luo J-C, Huang K-W, Leu H-B, Chen L-C, Hou M-C, Li CP, Lu CL, Lin HC, Lee FY, Lee SD. Randomised clinical trial: rabeprazole plus aspirin is not inferior to rabeprazole plus clopidogrel for the healing of aspirin-related peptic ulcer. Aliment Pharmacol Ther 2011;34:519-25. [Ref.ID 91484]
17.Enlace a cita original
Futura T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel n relation to CYP2C19 genotypes. Br J Clin Pharmacol 2010;70:383-92. [Ref.ID 89322]
18.Enlace a cita original
Abraham NS, Hlatky MA, Antman EM, Bhatt DL, Bjorkman DJ, Clark CB, Furberg CD, Johnson DA, Kahi CJ, Laine L, Mahaffey KW, Quigley EM, Shceiman J, Sperling LS, Tomaselli GF, American College of Cardiology Foundation Task Force on Expert Consensus Documents. ACCF/ACCG/AHA 2010 Expert Consensus Document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 Expert Consensus Document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010;56:2051-66. [Ref.ID 89235]
19.Enlace a cita original Cita con resumen
Anónimo. Inhibidores de la bomba de protones. ¿Cómo se utilizan?. Sacylite. Boletín de Informatión Terapéutica 2010;2:1-6. [Ref.ID 89207]
20.Enlace a cita original
García del Pozo J, Carvajal FJ. Utilización de antiulcerosos en España, 1992-2006. Agencia Española de Medicamentos y Productos Sanitarios (AEMPS) 2009:1-8. [Ref.ID 86459]
Seleccionar todas
 
 1 a 20 de 62 siguiente >>